Abstracts Archive - Page 162 of 2425 - ACR Meeting Abstracts

Abstract Number: 0570 • ACR Convergence 2024
Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients
Halah Alfatlawi¹, abdulmajeed alharbi², eun seo kwak², rawnag el sheikh² and nezam altorok², ¹the university of toledo, Toledo, OH, ²the university of toledo, Toledo
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial spine, commonly associated with extra-articular manifestations such as anterior uveitis (AU). Racial…
Abstract Number: 0740 • ACR Convergence 2024
Evaluation of an Accelerated Physical Aging Phenotype in Newly Diagnosed Patients with Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², seoidin McKittrick³, Robert Harrington⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³University of Limerick, Limerick, Ireland, ⁴St. James's Hospital, Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: Polymyalgia Rheumatica (PMR) is the most common inflammatory rheumatic disease in older adults, and aging has been postulated to be central to its pathophysiology.…
Abstract Number: 0774 • ACR Convergence 2024
A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose Glucocorticoids Compared to Stopping Glucocorticoids to Maintain Remission of Granulomatosis with Polyangiitis: The TAPIR Trial
Peter Merkel¹, Christian Pagnoux², Nader Khalidi³, Ulrich Specks⁴, Curry Koening⁵, Carol Langford⁶, Larry Moreland⁷, Paul Monach⁸, Jason Springer⁹, Shubhasree Banerjee¹, Simon Carette¹⁰, Rennie Rhee¹, Medha Soowamber¹¹, Kenneth Warrington⁴, Renee Borchin¹², Cristina Burroughs¹³, Carol McAlear¹, David Cuthbertson¹³ and Jeffrey Krischer¹³, ¹University of Pennsylvania, Philadelphia, PA, ²Mount Sinai Hospital, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Mayo Clinic, Rochester, MN, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Colorado, Denver, CO, ⁸VA Boston Healthcare System, Boston, MA, ⁹Vanderbilt University Medical Center, Franklin, TN, ¹⁰Mount Sinai Hosptial, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²University of South Florida, Tampa, ¹³University of South Florida, Tampa, FL
Background/Purpose: Use of low-dose glucocorticoids to maintain remission in patients with granulomatosis with polyangiitis (GPA) remains controversial. Additionally, there is no consensus on how to…
Abstract Number: 0809 • ACR Convergence 2024
The Utility of the sFlt1:PlGF Ratio to Rule out and Predict Preeclampsia in Women with Lupus
Megan Clowse¹, Kateena Addae-Konadu², Jerome Federspiel³, Jennifer Gilner², Andra James², Eugene Kovalik², Anika Lucas³, Laura Neil², Catherine Sims⁴, Amanda Snyderman², Samir Soneji² and Amanda Eudy⁵, ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Knightdale, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: Women with SLE have high rates of preeclampsia caused by poor placental vascularization. The FDA recently approved the ratio of two angiogenic factors, soluble…
Abstract Number: 0813 • ACR Convergence 2024
Investigating TASL, SLC15A4, & TLR7 Associated Risk SNPs in Systemic Lupus Erythematosus
Christina G. Bruxvoort¹, Faith A. Porter¹, Joshua W. Cavett¹, John A. Ice², Batool Bilal¹, R Hal Scofield¹ and Valerie M. Lewis¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OKC Veteran's Affairs Medical Center, Oklahoma City
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease that mostlyhas it onset among women between the ages 15–44. While the global pathogenic…
Abstract Number: 0791 • ACR Convergence 2024
Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset
Caroline Walton¹, Forrest Hurley², Liubov Arbeeva³, Stephen Messier⁴, Shannon Mihalko⁴, Jeffrey Katz⁵, Richard Loeser⁶, David Hunter⁷, Leigh Callahan⁸ and Amanda Nelson², ¹UNC School of Medicine, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, Carrboro, NC, ⁴Wake Forest University, Winston Salem, NC, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶University of North Carolina, Chapel Hill, NC, ⁷Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁸University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: Precision medicine has previously identified subgroups of clinical trial participants with knee osteoarthritis (kOA) that benefit more from a specific intervention than others. We…
Abstract Number: 0695 • ACR Convergence 2024
Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort
Stefano Di Donato¹, Marco Minerba², Enrico De Lorenzis³, Collette Hartley⁴, Lesley-Anne Bissell⁵, Rebecca Ross⁶ and Francesco Del Galdo⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Campus Bio-Medico University of Rome, Taranto, United Kingdom, ³Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
Abstract Number: 0581 • ACR Convergence 2024
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with reduced radiographic progression and improved quality of life among patients (pts) with PsA.1 Clinical advances made MDA…
Abstract Number: 0752 • ACR Convergence 2024
Non-classical Organ Involvement in Giant Cell Arteritis
Javier Narvaez-García¹, paola Vidal¹, Pol Maymó², Judith Palacios³, Martí Aguilar Coll¹, Monserrat Roig Kim¹, Laia De Daniel¹ and Joan Miquel Nolla¹, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge., Barcelona, Spain, ³Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain
Background/Purpose: The increasing use of imaging techniques, particularly 18F-FDG PET-CT, has significantly expanded our understanding of giant cell arteritis (GCA). Our aim was to examine…
Abstract Number: 0817 • ACR Convergence 2024
2024 Clinical Practice Guideline for the Diagnosis and Treatment of Chronic Nonbacterial Osteitis (CNO) in Adults
Elizabeth Winter, Olaf Dekkers and Anne Leerling, and the Expert Consensus Panel for Chronic Nonbacterial Osteitis (CNO) in Adults, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Adults with sterile bone inflammation are variably labelled as Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO)-syndrome, chronic nonbacterial osteomyelitis, chronic recurrent multifocal osteomyelitis (CRMO), pustulotic…
Abstract Number: 0823 • ACR Convergence 2024
A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis
Carol Langford¹, Nader Khalidi², Jason Springer³, Marcia Friedman⁴, Bernhard Hellmich⁵, Christian Pagnoux⁶, Natasha Dehghan⁷, Ora Singer⁸, Curry Koening⁹, Yih Chang Lin¹⁰, Paul Monach¹¹, Larry Moreland¹², Aurore Fifi-Mah¹³, Oliver Flossmann¹⁴, Lindsy Forbess¹⁵, Peter Lanyon¹⁶, Eamonn Molloy¹⁷, Ulrich Specks¹⁸, Robert Spiera¹⁹, Elaine Yacyshyn²⁰, Carol McAlear²¹, Cristina Burroughs¹⁰, Rachel Jones²², Rennie Rhee²¹, Rula A. Hajj-Ali²³, Kenneth Warrington¹⁸, David Cuthbertson¹⁰, Jeffrey Krischer¹⁰, David Jayne²² and Peter Merkel²¹, and the Vasculitis Clinical Research Consortium and the European Vasculitis Society, ¹Cleveland Clinic, Moreland Hills, OH, ²McMaster University, Hamilton, ON, Canada, ³Vanderbilt University Medical Center, Franklin, TN, ⁴Oregon Health and Science University, Portland, OR, ⁵Medius Kliniken, Kirchheim unter Teck, Germany, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁸University of Michigan, Huntington Woods, MI, ⁹University of Texas Dell Medical School, Austin, TX, ¹⁰University of South Florida, Tampa, FL, ¹¹VA Boston Healthcare System, Boston, MA, ¹²University of Colorado, Denver, CO, ¹³University of Calgary, Calgary, AB, Canada, ¹⁴Royal Berkshire Hospital, Reading, United Kingdom, ¹⁵Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶University of Nottingham, Nottingham, United Kingdom, ¹⁷St Vincent's University Hospital, Dublin, Ireland, ¹⁸Mayo Clinic, Rochester, MN, ¹⁹Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²⁰University of Alberta, Edmonton, AB, Canada, ²¹University of Pennsylvania, Philadelphia, PA, ²²University of Cambridge, Cambridge, United Kingdom, ²³Cleveland Clinic, Cleveland, OH
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a small-vessel vasculitis associated with frequent relapses. Following encouraging results from an open-label study, a randomized, double-blind, placebo-controlled trial…
Abstract Number: 0793 • ACR Convergence 2024
Secular Changes in Widespread Pain Across Two Generations: The Framingham Heart Study
David Felson¹, Juan-Pablo Zertuche¹, Nene Ukonu¹, mike LaValley², Margaret Clancy³ and Tuhina Neogi³, ¹Boston University, Boston, MA, ²Boston University School of Public Health, Arlington, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA
Background/Purpose: In the general community, widespread musculoskeletal pain is common and often disabling.. Epidemiologic surveys in the US and Europe in the 1990s and early…
Abstract Number: 0592 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Helena Marzo-Ortega¹, Philip Mease², Maxime Dougados³, Maureen Dubreuil⁴, Marina Magrey⁵, Martin Rudwaleit⁶, Maria Antonietta D'Agostino⁷, Christine de la Loge⁸, Ute Massow⁹, Vanessa Taieb¹⁰, Diana Voiniciuc¹¹ and Atul Deodhar¹², ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In the phase 3 studies, BE MOBILE 1 and 2, bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to…
Abstract Number: 0835 • ACR Convergence 2024
Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)
Yan Zhang¹, Brittany Ross¹, Diana Galvan¹, Yanjie Bao¹, Daiki Matsuda¹, Shaun Grosskurth¹, Iago Pinal-Fernandez², Maria Casal-Dominguez³, Gregor Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian Bot¹, Andrew Mammen² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²NIH, Bethesda, MD, ³NIH, Bathesda, MD
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID)…
Abstract Number: 0830 • ACR Convergence 2024
Activation of Autoreactive Lymphocytes in the Lung by STING Gain-of-function Mutation Expressing Radioresistant Cells
Kevin Gao¹, Kristy Chiang¹, Sharon Subramanian¹, Xihui Yin², Paul Utz³, Kerstin Nundel¹, Katherine A. Fitzgerald⁴ and Ann Marshak-Rothstein¹, ¹UMass Chan Medical School, Worcester, MA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Stanford, CA, ⁴UMass Chan Medical School, Worchester, MA
Background/Purpose: Gain-of-function mutations in STING, a critical mediator of dsDNA sensing, lead to a severe autoinflammatory syndrome known as STING-Associated Vasculopathy with onset in Infancy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].